December 1, 2022 | Targeted Therapies in Oncology

December 05, 2022

Wenxin (Vincent) Xu, MD, provides insight on biomarkers in renal cell carcinoma.

December 04, 2022

Refining current regimens and other emerging approaches will be delineated in melanoma, according to Omid Hamid, MD.

December 04, 2022

Although HER2 mutations present in many solid tumors, lung cancer is of particular interest because a significant number of mutations are found in the tyrosine kinase domain of the gene. Of those, about 90% take the form of insertions or deletions, according study findings.

December 03, 2022

In data from a first-in-human study of a novel MPS1 inhibitor in patients with advanced solid tumors, clinical activity was observed.

December 03, 2022

Updated findings from the TRIDENT-1 suggest that repotrectinib could represent a potential new treatment option for patients with ROS1- positive advanced non–small cell lung cancer, according to Byoung Chul Cho, MD, PhD.

December 02, 2022

Primary brain cancers are aggressive, resulting in low survival rates, and pose significant challenges to effective treatment, but ongoing studies signal hope for patients with there tumors.

December 02, 2022

Results of a study conducted by the Community Oncology Alliance showed significant reductions in screenings at the beginning of the COVID-19 pandemic.

December 02, 2022

According to John M. Burke, MD, significant attention has been paid in recent years to the problem of physician burnout and as oncologists continue to care for patients, it important to also care for themselves.